Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Fimasartan and Dapagliflozin (BR1019) in Healthy Adults
NCT05875259Phase 1Completed
- Sponsor
- Boryung
- Start
- May 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fimasartan and dapagliflozin in hypertension (HTN) and type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Boryung. Primary endpoints: Area Under the Concentration-Time Curve from time 0 to 24 hours at steady state and Maximum Plasma Concentration at steady state. Started May 2023; status: completed.
02
Drugs
fimasartandapagliflozin
03
Conditions
hypertension (HTN)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05875259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05875259.